Drug development for noncastrate prostate cancer in a changed therapeutic landscape

Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.160

Clinical trials are an essential aspect of drug development; however, in patients with non-castrate prostate cancer, the long natural history of the disease provides a major barrier to the introduction of new therapies. In this Review, the authors describe the potential of a novel, multi-arm, multistage, clinical trial project, with surrogate end points designed to fully reflect the effects of treatments, in transforming the treatment of patients with early stage prostate cancer, before the development of castration-resistant disease.

中文翻译：

---

治疗领域不​​断变化的非cast割型前列腺癌药物开发

治疗领域不​​断变化的非cast割型前列腺癌药物开发

Nature Reviews Clinical Oncology，在线发布：2017年10月17日；doi：10.1038 / nrclinonc.2017.160

临床试验是药物开发的重要方面。但是，在患有非cast割性前列腺癌的患者中，该疾病的悠久自然史为引入新疗法提供了主要障碍。在这篇综述中，作者描述了一个新颖的，多臂，多阶段，临床试验项目的潜力，其替代终点旨在完全反映治疗的效果，从而在治疗前对早期前列腺癌患者进行治疗。发生去势抵抗疾病。